<?xml version="1.0" encoding="utf-8" ?><rss version="2.0" xmlns:News="http://www.bing.com/news/search?q=biopharma&amp;form=QBNT&amp;format=rss"><channel><title>biopharma - BingNews</title><link>http://www.bing.com/news/search?q=biopharma&amp;form=QBNT&amp;format=rss</link><description>Search results</description><image><url>http://www.bing.com/rsslogo.gif</url><title>biopharma</title><link>http://www.bing.com/news/search?q=biopharma&amp;form=QBNT&amp;format=rss</link></image><copyright>Copyright \xc2\xa9 2026 Microsoft. All rights reserved. These XML results may not be used, reproduced or transmitted in any manner or for any purpose other than rendering Bing results within an RSS aggregator for your personal, non-commercial use. Any other use of these results requires express written permission from Microsoft Corporation. By accessing this web page or using these results in any manner whatsoever, you agree to be bound by the foregoing restrictions.</copyright><item><title>Aspire Biopharma to Present at the Life Sciences Investor Forum on June 25th</title><link>http://www.bing.com/news/apiclick.aspx?ref=FexRss&amp;aid=&amp;tid=6a32c27d71134bd5aee629dba4eacf7c&amp;url=https%3a%2f%2ffinance.yahoo.com%2fhealthcare%2farticles%2faspire-biopharma-present-life-sciences-145700541.html&amp;c=4192125762531612078&amp;mkt=en-us</link><description>Aspire Biopharma Holdings, Inc.’s (Nasdaq: ASBP) (“Aspire” or the “Company”), today announced that it will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on ...</description><pubDate>Wed, 17 Jun 2026 08:32:00 GMT</pubDate><News:Source>Yahoo Finance</News:Source><News:Image>http://www.bing.com/th?id=ONUT.rdT0F1ZA5aGNu8CQq-bHRQ&amp;pid=News</News:Image><News:ImageSize>w={0}&amp;h={1}&amp;c=14</News:ImageSize><News:ImageMaxWidth>600</News:ImageMaxWidth><News:ImageMaxHeight>400</News:ImageMaxHeight></item><item><title>Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma</title><link>http://www.bing.com/news/apiclick.aspx?ref=FexRss&amp;aid=&amp;tid=6a32c27d71134bd5aee629dba4eacf7c&amp;url=https%3a%2f%2fwww.manilatimes.net%2f2026%2f06%2f17%2ftmt-newswire%2fglobenewswire%2fconnect-biopharma-announces-completion-of-enrollment-of-phase-2-seabreeze-stat-asthma-study-evaluating-rademikibart-for-the-treatment-of-acute-exacerbations-in-asthma%2f2367545&amp;c=10203070481233628370&amp;mkt=en-us</link><description>&quot;Completion of enrollment in our Seabreeze STAT Asthma study marks another significant step in our mission to deliver the first biologic to treat patients suffering from an acute exacerbation of ...</description><pubDate>Wed, 17 Jun 2026 06:18:00 GMT</pubDate><News:Source>The Manila Times</News:Source></item><item><title>'Biopharma ecosystem is back to full health,' fueled by M&amp;A: PwC</title><link>http://www.bing.com/news/apiclick.aspx?ref=FexRss&amp;aid=&amp;tid=6a32c27d71134bd5aee629dba4eacf7c&amp;url=https%3a%2f%2fwww.fiercepharma.com%2fpharma%2fma-volume-and-value-indicate-biopharma-ecosystem-back-full-health-pwc&amp;c=824952809283699310&amp;mkt=en-us</link><description>With pharma and life sciences deal values surpassing $65 billion in Q1, marking the strongest quarter in the industry since 2020, analysts from PwC have declared that the “biopharma ecosystem is back ...</description><pubDate>Wed, 17 Jun 2026 01:59:00 GMT</pubDate><News:Source>Fierce Pharma</News:Source><News:Image>http://www.bing.com/th?id=ONUT.N6u-lLP7WP6GHIr7XHBQfw&amp;pid=News</News:Image><News:ImageSize>w={0}&amp;h={1}&amp;c=14</News:ImageSize><News:ImageMaxWidth>2447</News:ImageMaxWidth><News:ImageMaxHeight>1224</News:ImageMaxHeight></item><item><title>Sanofi and Owkin partner to develop next-generation biopharma AI agents</title><link>http://www.bing.com/news/apiclick.aspx?ref=FexRss&amp;aid=&amp;tid=6a32c27d71134bd5aee629dba4eacf7c&amp;url=https%3a%2f%2fwww.msn.com%2fen-us%2fnews%2ftechnology%2fsanofi-and-owkin-partner-to-develop-next-generation-biopharma-ai-agents%2far-AA257KyR&amp;c=2585781398024865780&amp;mkt=en-us</link><description>The partnership includes a five-year licence for Owkin’s K Pro, an AI platform designed to augment drug discovery.</description><pubDate>Mon, 08 Jun 2026 03:25:01 GMT</pubDate><News:Source>Pharmaceutical Technology on MSN</News:Source><News:Image>http://www.bing.com/th?id=ONUT.KJ8s8uZnrhf4pxXhvMtDCw&amp;pid=News</News:Image><News:ImageSize>w={0}&amp;h={1}&amp;c=14</News:ImageSize><News:ImageMaxWidth>1440</News:ImageMaxWidth><News:ImageMaxHeight>810</News:ImageMaxHeight></item><item><title>Quantum BioPharma (QNTM) Advances Proprietary Therapy for MS Treatment</title><link>http://www.bing.com/news/apiclick.aspx?ref=FexRss&amp;aid=&amp;tid=6a32c27d71134bd5aee629dba4eacf7c&amp;url=https%3a%2f%2ffinance.yahoo.com%2fsectors%2fhealthcare%2farticles%2fquantum-biopharma-qntm-advances-proprietary-185101269.html&amp;c=10892909703674586557&amp;mkt=en-us</link><description>Quantum BioPharma's LUCID-MS program is built around the unmet need for MS therapies capable of directly protecting or restoring myelin integrity that affects the loss of mobility or control of a ...</description><pubDate>Tue, 09 Jun 2026 12:01:00 GMT</pubDate><News:Source>Yahoo Finance</News:Source><News:Image>http://www.bing.com/th?id=ONUT.aBKX08XxuYwZrkGH3F06JA&amp;pid=News</News:Image><News:ImageSize>w={0}&amp;h={1}&amp;c=14</News:ImageSize><News:ImageMaxWidth>1200</News:ImageMaxWidth><News:ImageMaxHeight>494</News:ImageMaxHeight></item><item><title>Claritas Rx Introduces Consent Clearinghouse™ to Modernize Patient Consent Management Across Biopharma</title><link>http://www.bing.com/news/apiclick.aspx?ref=FexRss&amp;aid=&amp;tid=6a32c27d71134bd5aee629dba4eacf7c&amp;url=https%3a%2f%2flasvegassun.com%2fnews%2f2026%2fjun%2f15%2fclaritas-rx-introduces-consent-clearinghouse-to-mo%2f&amp;c=8836316626122474875&amp;mkt=en-us</link><description>Claritas Rx , the patient journey experts, today announced Consent Clearinghouse™, a dedicated solution for standardi ...</description><pubDate>Mon, 15 Jun 2026 22:22:00 GMT</pubDate><News:Source>Las Vegas Sun</News:Source></item><item><title>Aspire Biopharma acquires automotive supplier Dura Driver Control Systems in $30M deal (ASBP)</title><link>http://www.bing.com/news/apiclick.aspx?ref=FexRss&amp;aid=&amp;tid=6a32c27d71134bd5aee629dba4eacf7c&amp;url=https%3a%2f%2fwww.msn.com%2fen-us%2fautos%2fgeneral%2faspire-biopharma-acquires-automotive-supplier-dura-driver-control-systems-in-30m-deal-asbp%2far-AA25uJoL&amp;c=799819028490573623&amp;mkt=en-us</link><description>Aspire Biopharma has agreed to acquire Dura Driver Control Systems, a global automotive supplier with more than $200 million in annual revenue, significantly reshaping the company’s revenue base and ...</description><pubDate>Fri, 12 Jun 2026 07:20:03 GMT</pubDate><News:Source>InvestorsHub on MSN</News:Source><News:Image>http://www.bing.com/th?id=ONUT.F-so7lKFQwtoX-AFRUOzJg&amp;pid=News</News:Image><News:ImageSize>w={0}&amp;h={1}&amp;c=14</News:ImageSize><News:ImageMaxWidth>1200</News:ImageMaxWidth><News:ImageMaxHeight>659</News:ImageMaxHeight></item><item><title>What's Driving Biopharma M&amp;A Strategy in 2026</title><link>http://www.bing.com/news/apiclick.aspx?ref=FexRss&amp;aid=&amp;tid=6a32c27d71134bd5aee629dba4eacf7c&amp;url=https%3a%2f%2fwww.pharmtech.com%2fview%2fwhats-driving-biopharma-m-a-strategy-in-2026&amp;c=2267594125457458783&amp;mkt=en-us</link><description>Oncology remains the leading M&amp;A magnet, with ASCO data catalyzing interest in new combinations and next-generation modalities across major pharma buyers. GLP-1 deal interest is broadening beyond ...</description><pubDate>Tue, 16 Jun 2026 05:38:00 GMT</pubDate><News:Source>PharmTech</News:Source></item><item><title>Sunshine Biopharma Incorporated</title><link>http://www.bing.com/news/apiclick.aspx?ref=FexRss&amp;aid=&amp;tid=6a32c27d71134bd5aee629dba4eacf7c&amp;url=https%3a%2f%2fwww.cnn.com%2fmarkets%2fstocks%2fSBFM&amp;c=6777620305153269757&amp;mkt=en-us</link><description>View Sunshine Biopharma Incorporated SBFM stock quote prices, financial information, real-time forecasts, and company news from CNN.</description><pubDate>Fri, 03 Apr 2026 06:06:00 GMT</pubDate><News:Source>CNN</News:Source></item><item><title>Aspire Biopharma Announces Signing of Definitive Share Purchase Agreement to Acquire Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History ...</title><link>http://www.bing.com/news/apiclick.aspx?ref=FexRss&amp;aid=&amp;tid=6a32c27d71134bd5aee629dba4eacf7c&amp;url=https%3a%2f%2fwww.usatoday.com%2fpress-release%2fstory%2f34612%2faspire-biopharma-announces-signing-of-definitive-share-purchase-agreement-to-acquire-dura-driver-control-systems-a-leading-global-automotive-supplier-with-a-100-year-history-and-200m-in-2025-reven%2f&amp;c=1768570959869148110&amp;mkt=en-us</link><description>Adds an established global brand with scale in large and growing markets driven by trends in vehicle and mobility ...</description><pubDate>Fri, 12 Jun 2026 10:09:00 GMT</pubDate><News:Source>USA TODAY</News:Source></item><item><title>Quantum Biopharma Ltd. Subordinate Voting Shares Class B</title><link>http://www.bing.com/news/apiclick.aspx?ref=FexRss&amp;aid=&amp;tid=6a32c27d71134bd5aee629dba4eacf7c&amp;url=https%3a%2f%2fwww.cnn.com%2fmarkets%2fstocks%2fQNTM&amp;c=9215382737644117949&amp;mkt=en-us</link><description>View Quantum Biopharma Ltd. Subordinate Voting Shares Class B QNTM stock quote prices, financial information, real-time forecasts, and company news from CNN.</description><pubDate>Mon, 13 Apr 2026 06:26:00 GMT</pubDate><News:Source>CNN</News:Source></item><item><title>Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns</title><link>http://www.bing.com/news/apiclick.aspx?ref=FexRss&amp;aid=&amp;tid=6a32c27d71134bd5aee629dba4eacf7c&amp;url=https%3a%2f%2fmarkets.businessinsider.com%2fnews%2fstocks%2fquantum-biopharma-engages-stocks-news-for-investor-relations-marketing-services-and-lead-generation-campaigns-1036217234&amp;c=5294573441223288891&amp;mkt=en-us</link><description>Rafael Pereira of the Agency will be involved in providing the investor relations services to the Company. The Agency’s contact information is as follows: IR Agency LLC, 23 Downing Street, Newark NJ ...</description><pubDate>Tue, 02 Jun 2026 05:03:00 GMT</pubDate><News:Source>Markets Insider</News:Source></item></channel></rss>